TME Pharma N.V. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was EUR 6.74 million compared to EUR 15.13 million a year ago. Basic loss per share from continuing operations was EUR 1.34 compared to EUR 12.86 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2545 EUR | +3.88% | +2.41% | +10.65% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.65% | 7.79M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ALTME Stock
- News TME Pharma N.V.
- TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023